Fisher and Paykel Healthcare has experienced a year-to-date increase of around 52%, despite facing stock pressure after its latest performance announcement.
The company's price-to-earnings (P/E) ratio is currently a concern for investors, standing at 103. Even with a projected 40% profit increase, this ratio would only decrease to 60, which is much higher than the historical buying range of 20 to 25 preferred by experienced investors.
The company saw a surge in demand for masks and healthcare equipment during the Covid-19 pandemic, but as the healthcare sector transitions post-pandemic, Fisher & Paykel has shown growth through effective cost management strategies. Analysts currently have a hold rating on the stock, reflecting cautious optimism given its high valuation.